Ken Griffin Cerus Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.39 $26,010 - $36,567	15,300 Added 212.5%	22,500 $39,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.04 $6,318 - $7,956	-3,900 Reduced 35.14%	7,200 $12,000
Q1 2024 May 15, 2024	BUY	$1.66 - $2.42 $2,490 - $3,630	1,500 Added 15.63%	11,100 $20,000
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.35 $3,625 - $6,815	-2,900 Reduced 23.2%	9,600 $20,000
Q3 2023 Nov 14, 2023	SELL	$1.5 - $3.07 $22,050 - $45,129	-14,700 Reduced 54.04%	12,500 $20,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.9 $77,865 - $126,150	-43,500 Reduced 61.53%	27,200 $66,000
Q1 2023 May 15, 2023	BUY	$2.65 - $3.81 $72,080 - $103,632	27,200 Added 62.53%	70,700 $209,000
Q4 2022 Feb 14, 2023	BUY	$3.38 - $4.22 $70,304 - $87,776	20,800 Added 91.63%	43,500 $158,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.83 $84,035 - $142,835	-24,500 Reduced 51.91%	22,700 $82,000

156

147M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $317M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.